"Three Stocks to Monitor on Tuesday, Including Sea and Outset Medical"
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
Sea Ltd. Earnings Report: Sea Ltd. is expected to report quarterly earnings of 77 cents per share on revenue of $5.65 billion, with shares rising 2.7% to $159.20 in after-hours trading.
Outset Medical Inc. Financial Results: Outset Medical reported a quarterly loss of 69 cents per share, missing estimates, and cut its FY25 sales guidance, leading to a 23.4% drop in shares to $9.25.
Amdocs Ltd. Earnings Expectations: Analysts anticipate Amdocs Ltd. will post earnings of $1.82 per share on revenue of $1.15 billion, with shares slightly increasing by 0.1% to $85.61.
LivePerson Inc. Performance: LivePerson exceeded expectations with its third-quarter results and raised its FY25 sales guidance, resulting in a 16.4% increase in shares to $6.10.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DOX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DOX
Wall Street analysts forecast DOX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOX is 99.00 USD with a low forecast of 87.00 USD and a high forecast of 111.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 81.070
Low
87.00
Averages
99.00
High
111.00
Current: 81.070
Low
87.00
Averages
99.00
High
111.00
About DOX
Amdocs Limited is a provider of software and services to communications and media companies in both developed countries and emerging markets. The Company's offerings are based on a product and service mix, using technologies and methodologies, such as the cloud and cloud native, microservices, development and operations (DevOps), low-code/no-code, edge computing, open source, bimodal operations, Site Reliability Engineering (SRE) and increasing amounts of automation through standard information technology (IT) tools, open Application programming interface (APIs) and artificial intelligence (AI), generative artificial intelligence (GenAI), and machine learning (ML). Its comprehensive line of services is designed to address every stage of a service provider's lifecycle and includes consulting, delivery, quality engineering (testing), systems integration, operations, network services, experience-driven services, data, cloud, and content services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
European Market Resilience: Línea Directa Trading 32.2% Below Fair Value
- Market Recovery Signals: The STOXX Europe 600 Index rose by 0.77%, indicating positive economic data and earnings reports, while Germany's economy emerged from a two-year recession with modest growth, suggesting a revival in market activity.
- Línea Directa Valuation Analysis: Línea Directa Aseguradora is currently trading at €1.15, which is 32.2% below its estimated fair value of €1.69; despite a revenue growth rate of 6.4% annually, its net income increased to €59.67 million for the first nine months of 2025, indicating improved profitability.
- Cogelec Potential Opportunity: Cogelec SA is priced at €29.2, below its estimated fair value of €40.36, reflecting a 27.7% discount; although profit margins have declined to 6.5%, earnings are expected to grow at 35.7% annually, significantly outpacing the French market's growth rate of 11.9%, showcasing strong growth potential.
- LINK Mobility Optimistic Outlook: LINK Mobility Group Holding is trading at NOK 33.9, significantly below its fair value estimate of NOK 66.27, suggesting a 48.8% discount; despite a decline in profit margins from 2.5% to 1.5%, earnings are forecasted to grow over 71% annually, indicating substantial profit growth potential.
Continue Reading
Ion Beam Applications (IBAB) Trading 47.7% Below Fair Value Amid Growth Prospects
- Market Opportunities: Amid economic recovery, investors are increasingly focused on undervalued stocks, particularly those with strong fundamentals that may offer growth potential.
- Ion Beam Applications Overview: The company has a market cap of €438.41 million, with a current price of €14.98, significantly below its fair value of €28.64, indicating a 47.7% discount, despite revenue growth forecasts lagging behind the Belgian market.
- Earnings Growth Expectations: Ion Beam Applications anticipates annual earnings growth of 29.8%, surpassing market averages, and recent contracts with institutions like MD Anderson Cancer Center highlight robust demand for its advanced treatment systems.
- Munters Group Financial Status: With a market cap of SEK 30.69 billion and a current price of SEK 168.1, slightly below the fair value of SEK 188.68, the company faces challenges from high debt and volatile share prices, yet is expected to achieve a 37% annual profit growth.
Continue Reading